Domain Therapeutics Grants Bristol-Myers Squibb Non-Exclusive License for G protein-Coupled Receptor bioSens-All™ Technology
Technology provides access to new generation of sensitive biosensors to enhance drug discovery. Domain Therapeutics, a France- and Quebec-based biopharmaceutical company that specializes in the research and development of new drug candidates that target transmembrane receptors, announces the signing of a licensing agreement for its bioSens-All™ technology with Bristol-Myers Squibb, a global biopharmaceutical company whose mission is to discover, develop and deliver innovative...
Original Article: Domain Therapeutics Grants Bristol-Myers Squibb Non-Exclusive License for G protein-Coupled Receptor bioSens-All™ Technology
NEXT ARTICLE
More From BioPortfolio on "Domain Therapeutics Grants Bristol-Myers Squibb Non-Exclusive License for G protein-Coupled Receptor bioSens-All™ Technology"